



Government of Pakistan
Ministry of National Health Services, Regulations & Coordination
Drug Regulatory Authority Of Pakistan
Health & OTC Products Division (Non-Drugs)

Islamabad, the 21st October, 2021

“SAY NO TO CORRUPTION”

Subject: Submission of deficient information / documents

The applications of following applicants were placed before the Enlistment Evaluation Committee (EEC) in its 91st meeting held on 13th July, 2021 and the same have been deferred being deficient of the information / documents as specified in column (3) of the Table below which may be furnished within 20 days of uploading of this letter on official website of DRAP along with soft data as per **Annexed Format** at the end of this letter/document. Replies received after given time will not be entertained:-

S.No (1)	Brand name (2)	Decision (3)
M/s New Altaf Dawakhana, Near Railway Canal Bridge, Mianwali (E. No. 00792)		
1.	Libido Booster Capsule	Deferred for change of brand name
2.	Male Super Enhancement Capsule	Deferred for change of brand name
M/s. Arshzik (Veterinary), 23 Km Near Al-Ghani CNG, G.T. Road, Rawat, Rawalpindi (E. No. 00302)		
3.	Flunzatech HRe Oral Liquid	Deferred for the mrrmon tea extract which is common name of Ephedra a controlled substance / precursor
4.	Flunzatech HRe Oral Liquid	Deferred for the mrrmon tea extract which is common name of Ephedra a controlled substance / percursor
M/s Salbion Health Sciences (Pvt) Ltd., 23-Km, Sheikhpura Road, Lahore-Pakistan (E. No. 00647)		
5.	Ovifertil Tablet	Deferred for clarification of each two tablets
M/s Labbaik Herbal Pharma, Plot No. 122, Phase-II, M-3 Industrial Estate, Sahianwala, Faisalabad (E. No. 01182)		
6.	LABBAIK AKSEER BAWASEER TABLET	EEC decided to defer the application for enlistment for the change of brand name.
7.	LABBAIK IRON TABLET	EEC decided to defer the application for enlistment for the change of brand name.
8.	HUBB-E-PAICHAS TABLET	EEC decided to defer the application for enlistment for the change of brand name.
9.	LABBAIK HUBB E ATTHRA TABLET	EEC decided to defer the application for due to following reasons: <ul style="list-style-type: none"> • Brand name needs to be changed. • Provide monographs of Citrullus lanatus and mother pearl
10.	LABBAIK KHAMEERA GAOZUBAN SADA	EEC decided to defer the application for enlistment for the change of brand name.
11.	LABBAIK AKSEER BAWASEER CAPSULE	EEC decided to defer the application for enlistment for the change of brand name.
12.	LABBAIK TOLEED E SPERM CAPSULE	EEC decided to defer the application for enlistment for the change of brand name.
13.	LABBAIK PERFECT MUGHALIZ CAPSULE	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Brand name needs to be changed. • Justify the use of following homoeopathic ingredients in herbal formulation: “Dipterex odorata (HPI) and Stanum mettalicum (HPI)”.

Signature

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> • Provide undertaking regarding submission of stability data of the applied formulation on company's letter head duly signed by the owner of the firm.
14.	LABBAIK EZEDAYS CAPSULE	EEC decided to defer the application for enlistment for the change of brand name.
15.	LABBAIK ALSIRON CAPSULE	EEC decided to defer the application for enlistment for the change of brand name.
16.	LABBAIK CHOLESTEROL CAPSULE	EEC decided to defer the application for enlistment for the change of brand name.
17.	LABBAIK VITA SKIN CAPSULE	EEC decided to defer the application for enlistment for the change of brand name.
18.	LABBAIK HARMAIN PHAKKI	EEC decided to defer the application for enlistment for the change of brand name.
19.	LABBAIK SAFOOF TOLEED E SPERM	EEC decided to defer the application for enlistment for the change of brand name.
20.	LABBAIK SAFOOF ALSAR	EEC decided to defer the application for enlistment for the change of brand name.
21.	LABBAIK LAZEEZ CHURAN	EEC decided to defer the application for enlistment for the change of brand name.
22.	LABBAIK SAFOOF KIDNEY CARE	EEC decided to defer the application for enlistment for the change of brand name.
23.	LABBAIK AREENA HAIR OIL	EEC decided to defer the application for enlistment for the change of brand name.
24.	LABBAIK AMLA OIL	EEC decided to defer the application for enlistment for the change of brand name.
25.	LABBAIK ROGHAN DARD	EEC decided to defer the application for enlistment for the change of brand name.
26.	LABBAIK ROGHAN USHNA	EEC decided to defer the application for enlistment for the change of brand name.
27.	LABBAIK PIPRAMINT SYRUP	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Mention individual strengths of each ingredient being used in the formulation accordingly revise form-3.
28.	LABBAIK SANDUR MARHAM	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Justify the use of applied product as herbal/unani alternative medicine. • Provide evidence of competitor of applied formulation as herbal/unani alternative medicine. • Provide monograph of sandur.
29.	LABBAIK BAWASEERI MARHAM	EEC decided to defer the application for enlistment for the change of brand name.
M/s Winns International, 30-M Industrial Area, Kot Lakhpat, Lahore (E. No. 01165)		
30.	VIGORWIN CAPSULE	EEC decided to defer the application for enlistment for the change of brand name.
31.	WINSLIM CAPSULE	EEC decided to defer the application for enlistment for the change of brand name.
32.	MYOWIN CAPSULE	EEC decided to defer the application for enlistment for the change of brand name.
33.	WINSONATE SACHET	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • The applied formulation contains Ossein Mineral Complex which is a common molecule.
34.	KARNILOX LIQUID	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Provide evidence regarding unit dose filling and sealing machines of oral liquids sachet/ stick.

S.No	Brand name	Decision
(1)	(2)	(3)
35.	GESRID SYRUP	<ul style="list-style-type: none"> • EEC decided to defer the application for enlistment for the change of brand name.
36.	E - WIDE DROPS	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> • Form-3 needs to be revised w.r.t. mentioning the "IU per ml" strength of active ingredient, keeping in view the Recommended daily allowance of vitamin E.
37.	A - WIN DROP	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> • Brand name needs to be changed. • Form-3 needs to be revised w.r.t. mentioning the "IU per ml" strength of active ingredient, keeping in view the Recommended daily allowance of vitamin A.
38.	D - BONE DROPS	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> • The firm applied same formulation with insignificant difference, need clarification. • Form-3 needs to be revised w.r.t. mentioning the "IU per ml" strength of active ingredient, keeping in view the Recommended daily allowance of vitamin D3.
39.	D 5 DROPS	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> • The firm applied same formulation with insignificant difference, need clarification. • Form-3 needs to be revised w.r.t. mentioning the "IU per ml" strength of active ingredient, keeping in view the Recommended daily allowance of vitamin D3.
40.	D - BONE 6 DROPS	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> • The firm applied same formulation with insignificant difference, need clarification. • Form-3 needs to be revised w.r.t. mentioning the "IU per ml" strength of active ingredient, keeping in view the Recommended daily allowance of vitamin D3.
41.	D - BONE PLUS DROPS	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> • The firm applied same formulation with insignificant difference, need clarification. • Form-3 needs to be revised w.r.t. mentioning the "IU per ml" strength of active ingredient, keeping in view the Recommended daily allowance of vitamin D3.
42.	AD PLUS DROPS	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> • Brand name needs to be changed. • Form-3 needs to be revised w.r.t. mentioning the "IU per ml" strength of active ingredients, keeping in view the Recommended daily allowance of vitamin A, D and E.
43.	BIOWIN GEL	EEC decided to defer the application for enlistment for the change of brand name.
44.	BIOWIN PLUS GEL	EEC decided to defer the application for enlistment for the change of brand name.
45.	CAPSIWIN LOTION	<p>EEC decided to defer the application for enlistment due to following reasons:</p> <ul style="list-style-type: none"> • Brand name needs to be changed. • Form-3 needs to be revised w.r.t. mentioning the exact name of each ingredient as per monograph.
46.	DERMA WIN LOTION	<ul style="list-style-type: none"> • EEC decided to defer the application for enlistment for the change of brand name.

S.No	Brand name	Decision
(1)	(2)	(3)
47.	PAIN WIN PLUS CREAM	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • Brand name needs to be changed. • Form-3 needs to be revised w.r.t. mentioning the exact name of each ingredient as per monograph.
48.	PAIN WIN CREAM	EEC decided to defer the application for enlistment for the change of brand name.
49.	WINNS'S VAPOURUB	EEC decided to defer the application for enlistment for the change of brand name.
50.	WINNS'S VAPOURUB PLUS	EEC decided to defer the application for enlistment for the change of brand name.
M/s Pasteur & Fleming Pharmaceuticals Pvt. Ltd., Plot No. P-70-A, Road No.4, Phase-III, Industrial Estate, Hattar (01188)		
51.	FLUWEL SYRUP	EEC decided to defer the application for enlistment for the change of brand name.
Leads Nutraceutical, Plot No. 81-A, Street No. 6, Industrial Area, Sector I-10/3, Islamabad (E. No. 01190)		
52.	Multivit Phytase Granules	EEC decided to defer the application for enlistment on following reasons: <ul style="list-style-type: none"> • Provide specification of each ingredient. • Specify the type of Vitamin K, Antioxidant, 6-phytase and Vegetable proteins being used in the formulation and provide relevant monographs. • Mention salt of each elemental ingredient. • Provide all undertakings (Notarized stamp paper).
Falcon Laboratories (Pvt.) Limited, (E. No.00710) Special Industrial Estate, Behind Industrial Estate Office Risalpur, Nowshera		
53.	Kufsim Syrup	EEC decided to defer the application for enlistment for the change of brand name.
54.	PEDIFAL ORAL REHYDRATION SOLUTION	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • The firm applied ORS (Oral Rehydration Solution) which is added in the list of common molecules.
55.	Falcon's Femcare Capsule	EEC decided to defer the application for enlistment for the change of brand name.
56.	Falcon's Neurocalm Capsule	EEC decided to defer the application for enlistment for the change of brand name.
57.	APELYTE Sachet	EEC decided to defer the application for enlistment due to following reasons: <ul style="list-style-type: none"> • The firm applied ORS formulation which is added in the list of common molecules.
58.	FETOSLIM SACHET	<ul style="list-style-type: none"> • EEC decided to defer the application for enlistment for the change of brand name.
59.	Falcon's Bonyfal Tablet	<ul style="list-style-type: none"> • EEC decided to defer the application for enlistment for the change of brand name.
60.	Falcon's Cufsils Chewable Tablet	EEC decided to defer the application for enlistment for the change of brand name.
61.	Falcon's Hepacare Tablet	EEC decided to defer the application for enlistment for the change of brand name.
M/s. Gold Sheff International Nutraceutical, 537-F, Sunder Industrial Estate (PIE), Raiwind Road, Lahore		
62.	Calcigold Sachet	EEC decided to defer the application for enlistment for the change of brand name.
63.	Calcimax Sachet	EEC decided to defer the application for enlistment for the change of brand name.
64.	Calcip Sachet	EEC decided to defer the application for enlistment for the change of brand name.
65.	Calciway Sachet	EEC decided to defer the application for enlistment for the change of brand name.

S.No	Brand name	Decision
(1)	(2)	(3)
66.	Econil Sachet	EEC decided to defer the application for enlistment for the change of brand name.
67.	Femis Sachet	EEC decided to defer the application for enlistment for the change of brand name.
68.	Urimac Sachet	EEC decided to defer the application for enlistment for the change of brand name.
69.	Proseed Sachet	EEC decided to defer the application for enlistment for the change of brand name.
70.	Carnizym Sachet	EEC decided to defer the application for enlistment for the change of brand name.
Faran Pharmacy, Lahore		
71.	Asterias Rubens Potency	EEC decided to deferred the application for enlistment due to following reasons: <ul style="list-style-type: none"> Final opportunity for submission as The applied formulation contains sarcodes and evidence required that source should be free from TSE,BSE,Ecoli and Salmonella
72.	Bufo Rana Potency	EEC decided to deferred the application for enlistment due to following reasons: <ul style="list-style-type: none"> Final opportunity for submission as The applied formulation contains sarcodes and evidence required that source should be free from TSE,BSE,Ecoli and Salmonella
73.	Formica Rufa Potency	EEC decided to deferred the application for enlistment on following ground: <ul style="list-style-type: none"> The applied formulation contains sarcodes and source evidence that's its should be free from TSE,BSE,Eoli and salmonella
74.	Insulin Potency	EEC decide to deferred the application for enlistment due to following reasons: <ul style="list-style-type: none"> The primary source of insulin is required The handling,preparation and storage facilities are required
75.	Lachesis Potency	EEC decide to deferred the application for enlistment due to following reasons <ul style="list-style-type: none"> The applied formulation contains sarcodes and evidence that source should be free from TSE,BSE,ecoli and salmonella
76.	Tarentula Hispanica Potency	EEC decide to defer the application for enlistment on following grounds: <ul style="list-style-type: none"> the applied formulation contains sarcodes and source evidence should be free from TSE,ecoli salmonella
77.	Blatta Orientalis-Q Mother Tincture	EEC Decided to defre the application for enlistment on following grounds <ul style="list-style-type: none"> the applied formulation contains sarcodes and source evidence should be free from TSE,ecoli salmonella
78.	Cantharis-Q Mother Tincture	EEC Decided to defre the application for enlistment on following grounds <ul style="list-style-type: none"> the applied formulation contains sarcodes and source evidence should be free from TSE,ecoli salmonella
79.	Coccus Cacti Potency	EEC decided to defer the application for enlistment on following grounds: <ul style="list-style-type: none"> the applied formulation contains sarcodes and source evidence should be free from TSE,ecoli and salmonella
80.	Fel Tauri Potency	EEC decided to defer the application for enlistment on following grounds: <ul style="list-style-type: none"> source should be free from TSE,Ecoli and salmonella
81.	Lac Canium Potency	EEC decided to defer the application for enlistment on following grounds:

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> source should be free from TSE,Ecoli and salmonella
82.	Latrodectus Mactans Potency	EEC decide to defer the application for enlistment on following grounds: <ul style="list-style-type: none"> source should be free from TSE,Ecoli and salmonella
83.	Trombidium Potency	EEC decided to defer the application for enlistment for following grounds: <ul style="list-style-type: none"> source should be free from TSE,BSE, ecoli and salmonella
84.	Adreninum Potency	EEC decided to defer the application for enlistment for following grounds: <ul style="list-style-type: none"> source should be free from TSE,ecoli and salmonella
85.	Pancreatinum Potency	EEC decided to defer the application for enlistment on following grounds: <ul style="list-style-type: none"> source should be free from TSE,ecoli and salmonella
86.	Pituitarinum Potency	EEC decided to defer the application for enlistment on following grounds: <ul style="list-style-type: none"> source should be free from TSE,ecoli and salmonella
87.	Thyroidinum Potency	EEC decided to defer the application for enlistment on following grounds: <ul style="list-style-type: none"> source should be free from TSE,ecoli and salmonella
Alfalah Health Care (Pvt) Ltd Lahore		
88.	Okci Plus Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
89.	Fabize Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
Alpha Nutraceutical, Lahore		
90.	Bolac Syrup	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> Clarification regarding a product either applied product is herbal or Nutraceutical Fee paid for herbal product remaining fee of 1750 rupees in case of nutraceutical product
Angel Human Health Nutraceutical, Faisalabad		
91.	Notis Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.

S.No (1)	Brand name (2)	Decision (3)
92.	Multiaim Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
93.	Aim Fer Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
94.	Q-Vit Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
Animal Life Care, Bahawalpur		
95.	Masti Care Liquid	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Properly filled signed and stamped form 3 is required • Form 3 needs to be revised w.r.t showing specification of active ingredients in formulation brand name needs to be changed According to NOTIFCATION F.NO.4-2/2017-DD(H&OTC) in para (2)following information is required in support of the claim of availability of the proposed combination in local market for last 10years, <ul style="list-style-type: none"> • Company/firm establishment documents • Sales invoices including distribution record • Undertaking for the correctness of information duly signed by CEO/Managing partner/Managing director
96.	Calco-X Liquid	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Properly filled signed and stamped form 3 is required • Form 3 needs to be revised w.r.t showing specification of active ingredients in formulation brand name needs to be changed According to NOTIFCATION F.NO.4-2/2017-DD(H&OTC) in para (2)following information is required in support of the claim of availability of the proposed combination in local market for last 10years, <ul style="list-style-type: none"> • Company/firm establishment documents • Sales invoices including distribution record



S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> • Undertaking for the correctness of information duly signed by CEO/Managing partner/Managing director
97.	Uterus Care Majoon	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
98.	Life Red Shot Liquid	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
99.	Bio Care Liquid	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Properly filled signed and stamped form 3 is required • Form 3 needs to be revised w.r.t showing specification of active ingredients in formulation brand name needs to be changed According to NOTIFCATION F.NO.4-2/2017-DD(H&OTC) in para (2)following information is required in support of the claim of availability of the proposed combination in local market for last 10years, <ul style="list-style-type: none"> • Company/firm establishment documents • Sales invoices including distribution record • Undertaking for the correctness of information duly signed by CEO/Managing partner/Managing director
100.	Life Cool Liquid	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
101.	Life Stomach Liquid	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Properly filled signed and stamped form 3 is required • Form 3 needs to be revised w.r.t showing specification of active ingredients in formulation brand name needs to be changed According to NOTIFCATION F.NO.4-2/2017-DD(H&OTC) in para (2)following information is required in support of the claim of availability of the proposed combination in local market for last 10years, <ul style="list-style-type: none"> • Company/firm establishment documents • Sales invoices including distribution record



S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> Undertaking for the correctness of information duly signed by CEO/Managing partner/Managing director
102.	Toxy Care Liquid	<p>EEC decided to deferred the application for enlistment on following grounds:</p> <ul style="list-style-type: none"> Properly filled signed and stamped form 3 is required Form 3 needs to be revised w.r.t showing specification of active ingredients in formulation <p>brand name needs to be changed</p> <p>According to NOTIFICATION F.NO.4-2/2017-DD(H&OTC) in para (2)following information is required in support of the claim of availability of the proposed combination in local market for last 10years,</p> <ul style="list-style-type: none"> Company/firm establishment documents Sales invoices including distribution record Undertaking for the correctness of information duly signed by CEO/Managing partner/Managing director
103.	Life Fibro Care Majoon Powder	<p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
Apple Laboratories, Islamabad		
104.	I-Coline Syrup	<p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
105.	I-Coline Tablet	<p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
Atco HealthCare Pvt Ltd, Karachi		
106.	Numbify Cream	<p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>

S.No	Brand name	Decision
(1)	(2)	(3)
107.	Nobloat Oral Drop	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
108.	Propilus-S+ Anti Dandruff Lotion Lotion	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
109.	Nobloat Oral Solution	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
110.	Nobloat Chewable Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
111.	Hydrophil Moisturizing Lotion 20% Lotion	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
Avanza Health Care Pvt Ltd, Lahore		
112.	Tarocal-D Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.

S.No	Brand name	Decision
(1)	(2)	(3)
Bio Life Enterprises Nutraceuticals, Rawalpindi		
113.	Skipper Capsule	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Brand name needs to be changed • Form 3 needs to be revised w.r.t specification of active ingredients and signed and stamped
114.	Algae Cal Sachet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Brand name needs to be changed • Monograph of red algae calcium calcium is required • Form 3 needs to be revised w.r.t specification of active ingredients and signed and stamped
115.	Sb Berry Sachet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Brand name needs to be changed • Monograph of red algae calcium calcium is required • Form 3 needs to be revised w.r.t specification of active ingredients and signed and stamped • Confirmation of probiotic section
116.	Ovarifert Sachet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Brand name needs to be changed • Form 3 needs to be revised w.r.t specification of active ingredients and signed and stamped
117.	Inn-Bone Junior Sachet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Brand name needs to be changed • Monograph of red algae calcium calcium is required • Form 3 needs to be revised w.r.t specification of active ingredients and signed and stamped
118.	Bone Save Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Brand name needs to be changed • Form 3 needs to be revised w.r.t specification of active ingredients and signed and stamped
119.	Apday Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Brand name needs to be changed
120.	Inn-Bone Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Brand name needs to be changed • Monograph of red algae calcium calcium is required • Form 3 needs to be revised w.r.t specification of active ingredients and signed and stamped
121.	Glutone Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Brand name needs to be changed
122.	Algae Cal Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Brand name needs to be changed • Monograph of red algae calcium calcium is required • Form 3 needs to be revised w.r.t specification of active ingredients and signed and stamped
123.	Vitasyn Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in

S.No (1)	Brand name (2)	Decision (3)
		the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
Blossom Lab, Pvt, Ltd, Lahore		
124.	B-Slim Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
125.	Mins-M Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
126.	Gtg-Vit Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
Calgan Phyto Pharma Pvt Ltd, Lahore		
127.	Wepatol Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Brand name needs to be changed
128.	Truvit Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Brand name needs to be changed
129.	Mama Max Sachet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
Eon Pharmacy, Karachi		
130.	Fansud Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division



S.No (1)	Brand name (2)	Decision (3)
		of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
Etihad Herbal Industries, Lahore		
131.	Ziekuff Syrup	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Evidence of fee submission is required • brand name needs to be changed
132.	Arq-E-Ajwain Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
133.	Chuarqa Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
134.	Arq-E-Badian Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
135.	Arq-Mako Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
136.	Arq-E-Kasni Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
137.	Arq-E-Shahtra Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since

S.No	Brand name	Decision
(1)	(2)	(3)
		computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
138.	Bonecare Capsule	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • The applied formulation contains hyaluronic acid and chondrition sulphate which are in the list of common molecule • Brand name needs to be changed
139.	Ski-E-Sim Syrup	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Evidence of fee submission is required • Brand name needs to be changed
140.	Ski-E-Sim Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
Faisons-Meilleur International (Pvt) Ltd, Lahore		
141.	Femtil-D Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Brand name needs to be changed
142.	Cartina-Plus Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • The applied formulation contains glucosamine,chondrition sulphate and Hyaluronic acid which is in the list of common molecule
143.	Hi-Cell Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Brand name needs to be changed
144.	Big Bam Ointment	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Brand name needs to be changed
Falcon Herbal & Nutraceuticals, Nowshera		
145.	Sharbat-E-Podina Syrup	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Properly filled signed and stamped form 3 is required • Revised form 3 is required w.r.t specification of active ingredients in the formulation
146.	Sharbat-E-Pepermint Syrup	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Properly filled signed and stamped form 3 is required • Revised form 3 is required w.r.t specification of active ingredients in the formulation • The applied formulation contains Sodium bicarbonate which is the list of common molecule
147.	Sharbat-E-Faulad Syrup	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Properly filled signed and stamped form 3 is required

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> Revised form 3 is required w.r.t specification of active ingredients in the formulation
148.	Sharbat-E-Faulad Sumri Syrup	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> Properly filled signed and stamped form 3 is required Revised form 3 is required w.r.t specification of active ingredients in the formulation
Ferroza International Pharmaceutical Pvt Ltd, Lahore		
149.	Ferogut Sachet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> Confirmation of probiotic section
Filix Pharmaceuticals Pvt. Ltd., Islamabad		
150.	Testomen Surge Sachet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
151.	Rescozyme Q10 Capsule	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> Evidence of fee submission is required Properly filled signed and stamped form 3 is required Undertaking notarized regarding content and brand name is required Stability studies undertaking is required
Focus & Rulz Healthcare, Islamabad		
152.	Ossmin Suspension	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> The applied formulation contains Ossein mineral complex which is in the list of common molecule
153.	Serap Forte Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> The applied formulation contains Serratiopeptidase which is in the list of common molecule
154.	Ossmin Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> The applied formulation contains Ossein mineral complex which is in the list of common molecule
155.	Serap Ds Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> The applied formulation contains Serratiopeptidase which is in the list of common molecule
Genetics Healthcare, Lahore		
156.	Zevinc Syrup	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> The applied formulation contains Single sulphate as single ingredient which is in the list of common molecule
157.	Celeton Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant

S.No (1)	Brand name (2)	Decision (3)
		product application to check its status whether it has been disposed of or otherwise.
Global Laboratories Islamabad		
158.	Ovistol Sachet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Properly filled signed and stamped form 3 is required • Undertaking notarized regarding content and brand name is required • Brand name needs to be changed
159.	Glothione Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Properly filled signed and stamped form 3 is required • Source of proanthocyanidins is required • Revised form 3 is required w.r.t specification • Undertaking notarized regarding content and brand name is required
160.	Globolyte 500MI Strawberry Solution	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • The applied formulation contains ORS formulation which is in the list of common molecule • Properly filled signed and stamped form 3 is required • Undertaking notarized regarding content and brand name is required
161.	Cod Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Properly filled signed and stamped form 3 is required • Undertaking notarized regarding content and brand name is required • Brand name needs to be changed
162.	Eascon Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • The applied formulation contains Sennoside which is in the list of common molecule • Properly filled signed and stamped form 3 is required • Undertaking notarized regarding content and brand name is required
163.	Rogest Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • The applied formulation contains Progesterone which is registered as drug • Properly filled signed and stamped form 3 is required • Undertaking notarized regarding content and brand name is required
164.	Glutagen Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Properly filled signed and stamped form 3 is required • Undertaking notarized regarding content and brand name is required
Gluck Laboratories Pvt Ltd, Lahore		
165.	Antacon Plus Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.

S.No	Brand name	Decision
(1)	(2)	(3)
Green Health Nutraceuticals Laboratory, Peshawar		
166.	Gh Colic Drop	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
Green Which Natural Pharma Pvt. Ltd., Lahore		
167.	Green'S Hevit-M Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
168.	Green'S Heamo-M Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
169.	Win Cal-D Syrup	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Brand name needs to be changed • Properly filled signed and stamped form 3 is required • Differential fee as fee paid for herbal product
170.	Anir-Vit Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Brand name needs to be changed • Differential fee as fee paid for herbal product Confirmation regarding the applied products either for herbal products or Nutraceutical
171.	Oriange Super Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Brand name needs to be changed • Evidence of fee submission is required • Confirmation regarding the applied products either for herbal products or Nutraceutical
172.	Femiplex Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Brand name needs to be changed • Differential fee as fee paid for herbal product Confirmation regarding the applied products either for herbal products or Nutraceutical <ul style="list-style-type: none"> • The applied formulation contains toxic substance nux vomica and Hyocyamus niger
173.	Green Balm	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent

S.No	Brand name	Decision
(1)	(2)	(3)
		preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
174.	U-Plex-M Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Properly filled signed and stamped form 3 is required • Differential fee as fee paid for herbal product Monograph of coral calcium is required
175.	Multiplex Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Brand name needs to be changed • Differential fee as fee paid for herbal product Confirmation regarding the applied products either for herbal products or Nutraceutical • The applied formulation contains toxic substance <i>Hyocyamus niger</i>
176.	G-Dex	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • The applied formulation contains Iodine which is registered as a drug • Brand name needs to be changed • Differential fee as fee paid for herbal product Confirmation regarding the applied products either for herbal products or Nutraceutical
177.	Vet C Drop	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Brand name needs to be changed • Differential fee as fee paid for herbal product • Confirmation regarding the applied products either for herbal products or Nutraceutical
Helix Pharma (Pvt) Ltd, Karachi		
178.	Danz-Hc Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
Herbiotics Healthcare, Islamabad		
179.	Bex-D drops	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Brand name needs to be changed Evidence of fee submission is required
180.	Nutrigold Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Brand name needs to be changed Evidence of fee submission is required
181.	Multi-S-72 Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • The applied formulation contains magnesium hydroxide which is in the list of common molecule

S.No	Brand name	Decision
(1)	(2)	(3)
182.	Glim-Vit Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Brand name needs to be changed • Evidence of fee submission is required
183.	Glim-Max Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Brand name needs to be changed • Evidence of fee submission is required
184.	Ironia Syrup	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Brand name needs to be changed • Evidence of fee submission is required
185.	White-Vit Capsule	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Brand name needs to be changed • Evidence of fee submission is required
186.	B-Mega Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Brand name needs to be changed • Evidence of fee submission is required
187.	Dayvit Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Brand name needs to be changed • Evidence of fee submission is required
Herbtech Laboratories, Karachi		
188.	Ostcal-D Suspension	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Form 3 needs to be revised w.r.t specification of active ingredients • Brand name needs to be changed
189.	Calci4All Drop	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Form 3 needs to be revised w.r.t specification of active ingredients • Brand name needs to be changed
Himont Laboratories, Lahore		
190.	Oringa (Mango Sugar Fee)	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
Hizat Nutraceutical Industries, Peshawar		
191.	Zeecal D Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
Human Care Laboratories, Peshawar		

S.No (1)	Brand name (2)	Decision (3)
192.	Human Care'S Xinco Kidz Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
Inovics Healthcare,Rawalpindi		
193.	D Need Liquid	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
194.	B-Fair Shot	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
195.	D-Stone Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
196.	Diabesure Plus Milk Powder	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
197.	Femizen Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.

S.No	Brand name	Decision
(1)	(2)	(3)
198.	Femoril Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
199.	Healise Syrup	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Firm uses herbs in crud form • Confirmation Of herbal syrup section
200.	Tammex Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
201.	Versure Milk Powder	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
202.	Zaax Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
Izfaar Nutraceutical Industries, Lahore		
203.	Vixfar Ointment	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Properly filled signed and stamped form 3 is required • Brand name needs to be changed
Medicom Superior, Lahore		
204.	Wellgen Ispaghul Sachet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.



S.No	Brand name	Decision
(1)	(2)	(3)
Mediformers Nutraceutical, Lahore		
205.	Nerogin Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
Medinoon Research Laboratories, Lahore		
206.	Super Energy Syrup	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Brand name needs to be changed • Clarification regarding salt form of chelated iron is required
Miksons Healthcare SMC (Pvt) Ltd, Islamabad		
207.	Cadix Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
208.	H-Vit Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
209.	H-Vit Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
MSG Nutraceuticals, Islamabad		
210.	Bricks Plus Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Brand name needs to be changed • Evidence of fee submission is required
211.	Vitalin Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Brand name needs to be changed • Evidence of fee submission is required
212.	Kuffid Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent

S.No	Brand name	Decision
(1)	(2)	(3)
		preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
213.	Probo Sachet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
214.	Levevit Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Monograph of Asparagus powder extract is required • Properly filled signed and stamped form 3 is required
215.	Levegen Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Monograph of Soy Lecithin and Gotu kola powder extract is required is required • Properly filled signed and stamped form 3 is required
216.	Levecal Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Monograph of coral calcium is required Properly filled signed and stamped form 3 is required
Neutra Cure, Karachi		
217.	Caplop Tablets	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
218.	Vagicare Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
Nutrabiotics Nutritional Life Sciences, Peshawar		
219.	Ocuaid Pllus Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Form 3 needs to be revised w.r.t specification of active ingredients • Brand name needs to be changed • Clarification required regarding use of bilberry and either used in crude or extract form



S.No (1)	Brand name (2)	Decision (3)
220.	Ocuaid Plus Syrup	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Form 3 needs to be revised w.r.t specification of active ingredients • Brand name needs to be changed • Clarification required regarding use of bilbeery and either used in crude or extract form
Nutrasource International, Karachi		
221.	Digxil-H Suspension	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Firm uses herbs in crude form • Confirmation of herbal syrup section • Confirmation about applied product either herbal or nutraceutical Fee paid off herbal product and remaining fee is required • Brand name needs to be changed • The applied formulation contains toxic plant Berberis vulgaris
222.	Eatall Syrup	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Firm uses herbs in crude form • Confirmation of herbal syrup section • Confirmation about applied product either herbal or nutraceutical Fee paid off herbal product and remaining fee is required • Brand name needs to be changed
223.	Hicid Suspension	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Firm uses herbs in crude form • Confirmation of herbal syrup section • Confirmation about applied product either herbal or nutraceutical Fee paid off herbal product and remaining fee is required • Brand name needs to be changed • The applied formulation contains sodium bicarbonate which is in the list of common molecule
224.	Icecid Suspension	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Firm uses herbs in crude form • Confirmation of herbal syrup section • Confirmation about applied product either herbal or nutraceutical Fee paid off herbal product and remaining fee is required • Brand name needs to be changed • The applied formulation contains sodium bicarbonate which is in the list of common molecule
225.	Kuftec Syrup	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Firm uses herbs in crude form • Confirmation of herbal syrup section • Confirmation about applied product either herbal or nutraceutical Fee paid off herbal product and remaining fee is required • Brand name needs to be changed
Nutrimake Laboratories, Lahore		
226.	Multi Zinc Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Brand name needs to be changed • Evidence of fee submission is required



S.No (1)	Brand name (2)	Decision (3)
227.	Multiwait Syrup	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Brand name needs to be changed • Evidence of fee submission is required
228.	Multiwait Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Brand name needs to be changed • Evidence of fee submission is required
229.	Glucowait Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Brand name needs to be changed • The applied formulation contains Glucosamine sulphate and Chondroitin sulphate which are in the list of common molecule
230.	Sythin-Z Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Brand name needs to be changed • Evidence of fee submission is required
Pakistan Pharmaceutical Products Pvt Ltd, Karachi		
231.	Sleeppill (Melatonin) 2Mg Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • The applied formulation contains Melatonin which is in the list of common molecule • Brand name needs to be changed
232.	Sleeppill (Melatonin) 5Mg Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • The applied formulation contains Melatonin which is in the list of common molecule • Brand name needs to be changed
233.	Sleeppill (Melatonin) 3Mg Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • The applied formulation contains Melatonin which is in the list of common molecule • Brand name needs to be changed
234.	Glycifer Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Properly filled signed and stamped form 3 is required • Revised form 3 required w.r.t to specification
235.	Acid Gone Suspension	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Brand name needs to be changed • The applied formulation contains sodium bicarbonate which is in the list of common molecule
236.	Serrazen Forte Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • The applied formulation contains Serrapeptase which is in the list of common molecule
PDH Health Care, Lahore		
237.	Skinclear Cream	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.

S.No (1)	Brand name (2)	Decision (3)
Rayyon Skin & Healthcare, Karachi		
238.	Ack-Derm Soap	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
239.	OI Vee Soap	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
Scilife Pharma, Karachi		
240.	Scifol 400Mcg Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
Scotmann Pharmaceutical, Islamabad		
241.	Melaton 3Mg Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • The applied formulation contains Melatonin which is in the list of common molecule • Properly filled signed and stamped form 3 is required • Undertaking notarized regarding content and brand name is required
242.	Melaton 5Mg Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • The applied formulation contains Melatonin which is in the list of common molecule • Properly filled signed and stamped form 3 is required • Undertaking notarized regarding content and brand name is required
243.	Melaton Sr 2Mg Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • The applied formulation contains Melatonin which is in the list of common molecule • Properly filled signed and stamped form 3 is required • Undertaking notarized regarding content and brand name is required
244.	Sunnycal Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Properly filled signed and stamped form 3 is required • Undertaking notarized regarding content and brand name is required • Brand name needs to be changed



S.No (1)	Brand name (2)	Decision (3)
245.	Melaton Plus Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> The applied formulation contains Melatonin which is in the list of common molecule Properly filled signed and stamped form 3 is required Undertaking notarized regarding content and brand name is required
Sindhco Nutraceuticals, Kasur		
246.	Colimin Syrup	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> Firm uses herbs in crude form Clarification regrading herbal syrup section is required Brand name needs to be changed
247.	Colimin Drop	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> Firm uses herbs in crude form Clarification regrading herbal oral liquid section is required Brand name needs to be changed
248.	N-Zyme Syrup	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> Brand name needs to be changed
The Best Laboratories Lahore		
249.	Denorate Forte Drops	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
Trends Pharmaceuticals Lahore		
250.	Era Plus Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> Evidence of fee submission is required Brand name needs to be changed
Verbana International, Islamabad		
251.	Fitfat Powder	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
252.	V-Tox Powder	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> Properly filled signed and stamped form 3 is required Brand name needs to be changed
253.	Pro Fat Powder	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in

S.No	Brand name	Decision
(1)	(2)	(3)
		the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
254.	Cowtin Powder	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
Vernon Nutraceutical Pvt Ltd, Lahore		
255.	Gasrite Syrup	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Brand name needs to be changed • Revised form 3 w.r.t speciation of active ingredient is required
256.	G-Fate Syrup	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Brand name needs to be changed • Revised form 3 w.r.t speciation of active ingredient is required • Firm uses herbs in crude form • Clarification of herbal syrup section
257.	Gaspo-Nil Syrup	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Brand name needs to be changed • The applied formulation contains sodium bicarbonate which is in the list of common molecule • Revised form 3 w.r.t speciation of active ingredient is required
258.	Vernon Dyrol Syrup	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Firm uses herbs in crude form • Clarification of herbal syrup section • Brand name needs to be changed • Revised form 3 w.r.t speciation of active ingredient is required
259.	Vernon Podina Syrup	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Firm uses herbs in crude form • Clarification of herbal syrup section • Brand name needs to be changed • Revised form 3 w.r.t speciation of active ingredient is required
260.	Pipper Mint Syrup	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Brand name needs to be changed • Revised form 3 w.r.t speciation of active ingredient is required • Firm uses herbs in crude form • Clarification of herbal syrup section
261.	Leeco'S Flunac Syrup	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Firm uses herbs in crude form • Clarification of herbal syrup section

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> Brand name needs to be changed Revised form 3 w.r.t speciation of active ingredient is required
262.	Cofnex Syrup	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> Brand name needs to be changed Revised form 3 w.r.t speciation of active ingredient is required
263.	Vermon Antacid Syrup	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> Brand name needs to be changed Revised form 3 w.r.t speciation of active ingredient is required
264.	Leeco'S Rd Cough Syrup	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> Brand name needs to be changed
265.	Big-Cran Pouches	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> Firm uses herbs in crude form Clarification of herbal syrup section Proof of sachet general section
266.	Gink-Sr Syrup	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> Brand name needs to be changed Revised form 3 w.r.t speciation of active ingredient is required Firm uses herbs in crude form
267.	Ginvit Syrup	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> Firm uses herbs in crude form Clarification of herbal syrup section
268.	Vermon Fast Blood Syrup	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> Brand name needs to be changed Revised form 3 w.r.t speciation of active ingredient is required
269.	Mvita-X Syrup	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> Brand name needs to be changed Revised form 3 w.r.t speciation of active ingredient is required
Weather Folds Hattar		
270.	Vacinum Sachet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> Brand name needs to be changed Revised form 3 w.r.t speciation of active ingredient is required
Wilson's Healthcare, Islamabad		
271.	Wilson'S Fizzy Blackberry 10Mg Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> Properly filled signed and stamped form 3 is required Undertaking regarding content and brand name is required
272.	Wilson'S Fizzy Orangia 10Mg Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> Properly filled signed and stamped form 3 is required Undertaking regarding content and brand name is required
273.	Wilson'S Fizzy Pomegranate 10Mg Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> Properly filled signed and stamped form 3 is required

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> • Undertaking regarding content and brand name is required
274.	Wilson'S Fizzy Blackberry 50Mg Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
275.	Wilson'S Fizzy Orangia 50Mg Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Properly filled signed and stamped form 3 is required • Undertaking regarding content and brand name is required
276.	Wilson'S Fizzy Pomegranate 50Mg Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Properly filled signed and stamped form 3 is required • Undertaking regarding content and brand name is required
277.	Wilson'S Fizzy Blackberry 10Mg Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Properly filled signed and stamped form 3 is required • Undertaking regarding content and brand name is required
278.	Wilson'S Osteofiz (Orange) Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
279.	Wilson'S Fizzy Orangia 50 Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
280.	Wilson'S Fizzy Strawberry 50 Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Properly filled signed and stamped form 3 is required • Undertaking regarding content and brand name is required
281.	Wilson'S Osteofiz (Mango) Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
282.	Wilson'S Fizzy Cola 50Mg Tablet	EEC decided to deferred the application for enlistment on following grounds: <ul style="list-style-type: none"> • Properly filled signed and stamped form 3 is required

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> Undertaking regarding content and brand name is required
Adcok Pharmaceutical (Pvt) Ltd, Lahore		
283.	Rylo-Ad Drops	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
284.	Fancid Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
285.	Zixvy Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
286.	Gaxry Tablet	Deferred for submission of Signed and stamped Form 3.
287.	Ilmf Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
288.	Orbitol Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
289.	Oxita Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
Alfalah Health Care (Pvt) Ltd Lahore		
290.	Levo Cid Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
291.	Ivysip Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
292.	Prevocid Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
293.	Vitlife Tablet	Deferred for following reasons:

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
294.	Promom Advance Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
295.	Maxman Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
296.	Alvo-Cal Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
297.	Spremax Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
298.	Ovegen Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
299.	Healfer Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
Angel Human Health Nutraceutical, Faisalabad		
300.	Hizer Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
301.	Valta Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
302.	Cran-X Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required.



S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> Brand name undertaking and content undertaking are required.
303.	Kidz-Ad Drop	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
304.	Ko-Line Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
305.	Immunovit Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
306.	Hi-Roz Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
307.	Lemacule Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
308.	Iconate-Fa Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
309.	Dia-Beta Plus Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
310.	Folixa-N Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
311.	Xeetonin Drop	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
312.	Bvita-Da Drop	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence.

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> Form 3 is required. Brand name undertaking and content undertaking are required.
313.	Spasminil Drop	Deferred for change of brand name and submission of Fee evidence of spasminil drop.
314.	Invecal Syrup	Deferred for submission of Fee evidence of invecal syrup
315.	Folixa Plus Tablet	Deferred for submission of Fee evidence of folixa plus tablet.
316.	Nutriwin Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
317.	Cocarti Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
318.	Contacool Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
319.	Enzic Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
320.	Nutriwin Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
Animal Life Care, Bahawalpur		
321.	Life Fibro Care Majoon	Deferred for submission of monograph of hydrargyry subchloridum.
322.	Anza Pharma, Lahore	
323.	Profer Plus Sachet	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
324.	Antacon Soda Sachet	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
325.	C-Well Grow Oral Drop	Deferred for change of brand name.
326.	C-Well M Oral Drop	Deferred till finalization of common molecules list.
327.	C-Well D Oral Drop	Deferred for change of brand name.
328.	C-Well AD Oral Drop	Deferred for change of brand name.
329.	C-Well BG Oral Drop	Deferred till finalization of common molecules list.
330.	C-Well Grow Syrup	Deferred for change of brand name.

S.No (1)	Brand name (2)	Decision (3)
331.	Coral+ Tablet	Deferred for change of brand name.
332.	Brotis Oral Drops	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
Avant Pharmaceutical, Karachi		
333.	Inglot-D Syrup	Deferred for submission of Signed and stamped Form 3.
334.	Avezinc Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
335.	Inglot-D Tablet	Deferred for submission of Signed and stamped Form 3.
Bio Life Enterprises Nutraceuticals, Rawalpindi		
336.	Furty-X Capsule	Deferred for following reasons: <ul style="list-style-type: none"> • Brand name needs to be changed. • Monographs of chlorophytum borivillanum and emblica officinalis are required.
337.	Glo+ Capsule	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
338.	Ainfar-X Plus Capsule	Deferred for following deficiencies: <ul style="list-style-type: none"> • Brand name needs to be changed. • Yohimbine is added in common molecules list.
339.	Boneeta+ Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
340.	Forliv Tablet	Deferred for submission of monographs of malus domestica and fragaria and Firm applied same formulation in same dosage form under different brand name, needs clarification in this regard.
341.	Heplay Tablet	Deferred for submission of monographs of malus domestica and fragaria and Firm applied same formulation in same dosage form under different brand name, needs clarification in this regard.
342.	PCOS-Fix Tablet	Deferred for change of brand name.
Bio Serve Pharma, Karachi		
343.	Cranbest Sachet	Deferred for change of brand name.
344.	Hederaser Plus Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
345.	Servegin Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
346.	Hederaser Syrup	Deferred for following reasons:

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
347.	Glucoserve Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
348.	Hivit Tablet	Deferred for change of brand name.
Biotron Altair Pakistan, Karachi		
349.	Electrolade Sachet	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
350.	Lactyd Drop	Deferred till finalization of common molecules list.
351.	Biotron Gripe Water	Deferred for following reasons: <ul style="list-style-type: none"> Signed and stamped form 3 is required. Brand name change and contents undertakings are required. Fee evidence is required.
352.	Emty Syrup	Deferred till finalization of common molecules list.
353.	Drip Drop ORS Sachet	Deferred till finalization of common molecules list.
Bless Laboratories Pvt. Ltd., Lahore		
354.	D-Ferb Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
355.	Hizyme Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
356.	Glovit Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
Burj Healthcare, Karachi		
357.	Ovit M Soft Gelatin Capsule	Deferred for following reasons: <ul style="list-style-type: none"> Availability of softgel capsule section is required. GMP compliance report is required.
358.	Everplan Sachet	Deferred till submission of GMP compliance report and change of brand name..
359.	Gerifex Syrup	Deferred till submission of GMP compliance report.
360.	Ovit M Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required.

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> Brand name undertaking and content undertaking are required.
361.	Foligain Tablet	Deferred for change of brand name and submission of GMP compliance report.
Cidex Laboratories, Peshawar		
362.	Welmeg Tablet	Deferred for submission of stability of omega 3 in tablet dosage form.
363.	Mactorfer Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
Eon Pharmacy, Karachi		
364.	Neocal Vit D Syrup	Deferred due to following reasons: <ul style="list-style-type: none"> Firm applied fee of Neocal Vit D syrup while Submitted Form 3 is of Neo-Calvit Syrup, needs clarification in this regard. Brand name needs to be changed in either case.
365.	Calceon Syrup	Deferred for change of brand name.
366.	Multeon Syrup	Deferred for change of brand name.
Etihad Herbal Industries, Lahore		
367.	Solar Capsule	Deferred for following reasons: <ul style="list-style-type: none"> Form 3 to be signed by CEO/owner and stamped. Brand name needs to be changed.
368.	Liver Age Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Silymarin is added in common molecules list. Form 3 to be signed by CEO/owner and stamped. Monograph of cardus marianus extract is required.
Faisons-Meilleur International (Pvt) Ltd, Lahore		
369.	Cam-D Tablet	Deferred for change of brand name and submission of fee evidence.
370.	Vitanol Gold Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Brand name needs to be changed. Individual strength of lutein and zeaxanthin are required. Stability of DHA (omega 3) in tablet dosage form is required.
371.	Nucran Sachet	Deferred since fee challan is not endorsed by concerned division of DRAP and change of brand name.
372.	Pepsid Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
373.	Ovi-Safe Sachet	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
374.	Life Shine Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
375.	Ortho-Fact Tablet	Deferred till finalization of common molecules list and change of brand name and Fee challan is not endorsed by concerned division of DRAP.
376.	Calwell Sachet	Deferred for following reasons:

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> • Monograph of red algae calcium is required. • Brand name needs to be changed.
377.	Q-Fenz 10 Tablet	Deferred since Fee challan is not endorsed by concerned division of DRAP.
Focus & Rulz Healthcare, Islamabad		
378.	Serap Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
Galen Nutraceuticals, Islamabad		
379.	Mint-G	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
Genetics Healthcare, Lahore		
380.	Preus Tablet	Deferred for submission of monograph of pelargonium sidoides extract.
Greektec Nutraceutical, Karachi		
381.	Fertizyme Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
Helix Pharma (Pvt) Ltd, Karachi		
382.	Danz-Q Tablet	Deferred till finalization of common molecules list.
Herbotics Healthcare, Islamabad		
383.	Chest Best Syrup	Deferred since Firm has submitted two files with same brand name having different formulations, needs clarification in this regard.
384.	Humpty Dumpty Syrup	Deferred for change of brand name.
385.	Ceze-D Plant Tablet	Deferred since Firm has submitted two files with same brand name having different formulations, needs clarification in this regard
386.	Sugnovit Tablet	Deferred since Firm has submitted two files with same brand name having different formulations, needs clarification in this regard
387.	Anzer Plus Syrup	Deferred since Fee challan is not endorsed by concerned division of DRAP and Firm has submitted two files with same brand name having different formulations, needs clarification in this regard
388.	Tribmax Tablet	Deferred till finalization of common molecules list.
389.	Sernol Tablet	Deferred for submission of monograph of raspberry ketone.
390.	Stro-M Tablet	Deferred till finalization of common molecules list.
391.	Medigreen Folic Acid Tablet	Deferred since Firm has submitted two files with same brand name having different formulations, needs clarification in this regard.
Hinucon, Karachi		
392.	Pixel Combi Capsule	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
393.	Pixel C Chewable Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.

S.No (1)	Brand name (2)	Decision (3)
394.	Fibocell Powder	Deferred for submission of availability of probiotic section.
Hisun Pharmaceutical Industries, Swabi		
395.	Krone-12 Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
396.	Hemukon Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
397.	Orivamin Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
398.	Mayokon Sachet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
399.	Orivamin Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
Izfaar Nutraceutical Industries, Lahore		
400.	Brosis Gold Plus Capsule	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
401.	Soda-H2 Powder	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
402.	Super Stem Liquid	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
403.	Vimin Plus (Vet)	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
404.	Trilong Capsule	Deferred for following reasons:

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
405.	Trisom Capsule	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
406.	Enufmom Powder	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
407.	Livofar Capsule	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
408.	Memogen Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
King Camco Pharma Nutraceutical, Lahore		
409.	Bestrine Mouthwash	Deferred till finalization of common molecules list.
410.	Bon-Cal D Tablet	Deferred for change of brand name.
411.	Kamcid Plus Syrup	Deferred for change of brand name.
412.	Bon Calacter Tablet	Deferred for change of brand name.
413.	Folic Plus Tablet	Deferred since Application is devoid of following deficiencies: <ul style="list-style-type: none"> Form 3 is un-signed and un-stamped. Contents and brand name change undertakings are required. Fee evidence is required.
414.	Active Bone Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
415.	La-Cid Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
416.	Clean Cough Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
Mazton Pharmaceuticals, Lahore		
417.	Kelo-Cote Gel	Deferred for following reasons:

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
Medicom Superior, Lahore		
418.	Curqu-Max Tablet	Deferred for change of brand name.
419.	Pregna-Mate Tablet	Deferred for change of brand name.
420.	Biocal+D Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Monograph of red algae calcium is required. • Brand name needs to be changed.
421.	Vita-Gold Tablet	Deferred for change of brand name.
422.	Men'S Gold Capsule	Deferred for submission of Monograph of eurycoma longifolia extract and change of brand name.
423.	Ortho-Plus Tablet	Deferred till finalization of common molecules list and change of brand name.
424.	Bright Start Drop	Deferred for change of brand name.
Miksons Healthcare SMC (Pvt) Ltd, Islamabad		
425.	Hepato Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
426.	Q-Nit Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
427.	Vitm-F Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
428.	Mind blow Syrup	Deferred till finalization of common molecules list.
429.	Milci-Cal Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
430.	Oscan Tablet	Deferred for change of brand name.
431.	Ferosan Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
432.	Epimax Syrup	Deferred for change of brand name.
433.	Calfomix Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
434.	Methyl-F Tablet	Deferred for following reasons:

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
435.	Mikson-D Drop	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
436.	Convit-3 Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
Mod Herbs, Karachi		
437.	Kidnifit Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
438.	Marex-G Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
439.	Moplus Capsule	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
440.	Timin-P Capsule	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
441.	Dayfun-3 Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
442.	Nerbest Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
443.	Maca Man Sachet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required.

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> Brand name undertaking and content undertaking are required.
444.	Marex-G Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
445.	Livcap-S Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
446.	Nerbest Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
447.	Livcap-S Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
448.	Minvit Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
Montis (Pvt) Ltd, Lahore		
449.	Kraze Moisturizing Cream	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
450.	Prozinc Clean Shampoo	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
451.	Ban Sun Sc Spf 40 Gel	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
MSG Nutraceuticals, Islamabad		
452.	Floline Syrup	Deferred for submission of signed and stamped Form 3
453.	Encim Tablet	Deferred for submission of Stability of omega 3 in tablet.
Novamed Healthcare, Lahore		
454.	Avelia Tablet	Deferred for submission of Form 3 to be signed by owner/ CEO of firm.
Nutrasource International, Karachi		
455.	Lexicof Syrup	Deferred for following reasons:

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> change of brand name and submission of differential fee. Availability of herbal section is required.
456.	Mukaim Suspension	Deferred for change of brand name and submission of differential fee.
457.	Pakcid Suspension	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
458.	Saracid Suspension	Deferred for change of brand name and submission of differential fee.
459.	Unicid Suspension	Deferred for change of brand name, submission of differential fee and till finalization of common molecules list.
460.	Liskovit-M Syrup	Deferred for change of brand name.
Nutrifactor Laboratories (Pvt) Ltd, Faisalabad		
461.	Cufex Syrup	Deferred for change of brand name.
462.	Neutral Syrup	Deferred for change of brand name.
Nutrimed Laboratories, Karachi		
463.	Ironax Syrup	Deferred for change of brand name.
464.	Ironac Tablet	Deferred for change of brand name.
465.	Toux Drops	Deferred for change of brand name.
466.	Bonaq Drops	Deferred for submission of Monographs of all ingredients in extract form.
Nutrix Health Care, Faisalabad		
467.	Flurex Sachet	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
468.	Flurex Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Evidence of safety profile of Sambucus nigra is required. Monographs of echinacea purpurea, pinus pinaster extract, lavendulan angustifolia are required.
469.	Flurex Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Evidence of safety profile of Sambucus nigra is required. Monographs of echinacea purpurea, pinus pinaster extract, lavendulan angustifolia are required.
470.	Hepsil Suspension	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
471.	Jyf-Zar Syrup	Deferred for submission of monograph of apple extract.
472.	Nix Syrup	Deferred since Application is devoid of following deficiencies: <ul style="list-style-type: none"> Form 3 is un-signed and un-stamped. Contents and brand name change undertakings are required. Fee evidence is required.
473.	Xeebon Plus Tablet	Deferred since Application is devoid of following deficiencies: <ul style="list-style-type: none"> Form 3 is un-signed and un-stamped. Contents and brand name change undertakings are required. Fee evidence is required.
474.	Chol-D Stat Soft Capsule	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence.

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> Form 3 is required. Brand name undertaking and content undertaking are required.
475.	Foliks Soft Capsule	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
476.	Multi-G Soft Capsule	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
477.	Bone-D Soft Capsule	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
478.	Reox Soft Capsule	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
479.	White Cal-D Soft Capsule	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
480.	Bone-D Soft Capsule	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
481.	Chol-D Stat Soft Capsule	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
482.	Mutli-G Soft Capsule	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
483.	E-Day Soft Capsule	Deferred for change of brand name.
484.	Caltrum Soft Capsule	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
485.	Foliks Soft Capsule	Deferred since Application is devoid of following deficiencies:

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> Form 3 is un-signed and un-stamped. Contents and brand name change undertakings are required. Fee evidence is required.
486.	Pinq-D Suspension	Deferred since Application is devoid of following deficiencies: <ul style="list-style-type: none"> Form 3 is un-signed and un-stamped. Contents and brand name change undertakings are required. Fee evidence is required.
Oasis Pharma, Lahore		
487.	Osilite (Oral Electrolyte Solution) Liquid	Deferred till finalization of common molecules list.
488.	Pefcect Sachet	Deferred for following reasons: <ul style="list-style-type: none"> Firm submitted fee of Pefcect sachet (probiotic) while submitted Form 3 is of calcee plus sachet, needs clarification in this regard. Firm has changed formulation from probiotic to vitamins. In this regard, if firm intends to change formulation then firm is required to submit new application along with prescribed fee.
Olio Pharma Inc, Lahore		
489.	Men'S Formula Tab Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
490.	Women'S Formula Tab Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
491.	Vigomate Capsule	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
Opal Laboratories, Karachi		
492.	Ven-Berry Sachet	Deferred for submission of Form 3 to be signed by CEO/owner of company.
Paksons Neuro, Kabirwala		
493.	Nausenil Plus Syrup	Deferred till finalization of common molecules list.
494.	Hair Folligen Tablet	Deferred for change of brand name.
495.	Appisure Syrup Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Brand name needs to be changed. Monograph of cuminum cymium extract is required.
496.	Plexyfer Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
Paragon Herbal Laboratories, Lahore		
497.	Calci-Loc Tablet	Deferred for change of brand name.
Parina Pharma Pvt Ltd, Karachi		
498.	Colinor Stick	Deferred for following reasons: <ul style="list-style-type: none"> Monograph of orafti GR in required.

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> Manufacturing process of stick and in which section it will be formulated as dosage form, is required.
499.	Poly+Aid Ointment	Deferred for change of brand name.
500.	Mukaim (Strawberry) Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
501.	Gum Safe Solution	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
Pharma International, Karachi		
502.	Ginsana G115 Capsule	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
Phytotia Laboratory, Peshawar		
503.	Calcfit Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
504.	Kemivit Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
505.	Orthomax-D Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
506.	Calmax Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
507.	Ferimax Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
508.	Vitsmax Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.

S.No (1)	Brand name (2)	Decision (3)
509.	Locid Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
510.	Herbecough Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
Polyfine Nutra-Sciences, Peshawar		
511.	Carol-D Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
512.	Circarest Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
513.	Silycolin Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
514.	Glucomin Plus Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
515.	Enforta Capsule	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
QH Health (Private) Limited, Karachi		
516.	Trick-D Junior Oral Drop	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
517.	Folift 300Mg Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
Royal Laboratoies Lahore		
518.	Pimvit-G Tablet	Deferred for following reasons:

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
519.	Nomin Drop	Deferred till finalization of common molecules list (melatonin).
Saviour Pharma, Lahore		
520.	Shapes Tablet	Deferred for submission of Monographs of phaseolulus vulgaris extract and garcinia gambogia extract and change of brand name.
521.	Step-10 Tablet	Deferred for change of brand name.
Scotmann Pharmaceutical, Islamabad		
522.	Sun-D 5000IU Tablet	Deferred for submission of Signed and stamped Form 3.
Sefon Pharma, Sargodha		
523.	Epatonic Plus	Deferred for following reasons: <ul style="list-style-type: none"> Firm submitted fee of hepatic plus liquid while submitted form 3 is of Epatonic plus liquid, needs clarification in this regard. Brand name needs to be changed in either case.
524.	Lactomin Gold	Deferred for following reasons: <ul style="list-style-type: none"> Strength of all ingredients per serving dose is required.
525.	Livosef Extra Powder	Deferred for change of brand name and Strength of all ingredients per serving dose is required.
526.	Pulmopoul Super Liquid	Deferred for following reasons: <ul style="list-style-type: none"> Monographs of gypsum fibrosum and prunus dulcis extract are required. Brand name needs to be changed. Strength of all ingredients per serving dose is required.
527.	Coolant-C liquid	Deferred for following reasons: <ul style="list-style-type: none"> Strength of all ingredients per serving dose is required. Brand name needs to be changed.
528.	Coolant C4T Liquid	Deferred for following reasons: <ul style="list-style-type: none"> Strength of all ingredients per serving dose is required. Brand name needs to be changed.
Selmore Agencies (Pvt) Ltd, Lahore		
529.	Covtec Liquid	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
530.	Rendo-S	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
531.	Phopholigo Liquid	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
532.	No Heat-S Soluble Powder	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.

S.No (1)	Brand name (2)	Decision (3)
533.	Bio-Berry Liquid	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
534.	Cidotec Liquid	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
535.	C-Star	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
536.	Viba Zone	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
537.	Biogen-S Soluble Powder	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
538.	Pacom-A	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
539.	Pacomcid	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
540.	Paravita Liquid	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
541.	Vitro-S	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
542.	Liversol	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required.

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> Brand name undertaking and content undertaking are required.
543.	Biogen	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
SHS Nutrition, Karachi		
544.	Acti Life M 50+ Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
545.	Acti Life M Capsule	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
546.	Pregnable M Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
547.	Foliwell Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
548.	Stimulinds Capsule	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
549.	Acti Life F Capsule	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
550.	Proganycare Capsule	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
551.	Pregnable F Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
552.	Stimulin Ds Capsule	Deferred for following reasons:

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
553.	Acti-Joint Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
554.	Bonniecure Capsule	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
555.	Acti Life F 50+ Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
556.	Bonniecure Capsule	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
557.	Bonniecure Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
558.	Joggle Box Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
559.	Bonetab Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
Sigma Pharma International, Karachi		
560.	Nb Cranberry Fruit 4200Mg Plus Vitamin C	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
561.	Nb Ginko Biloba 60Mg Capsule	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required.



S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> Brand name undertaking and content undertaking are required.
562.	Nb 5-Htp 100Mg Capsule	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
Simbro HealthCare, Lahore		
563.	Meth-D Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
564.	Brocal Tablet	Deferred for change of brand name.
565.	CSH Late Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Glucosamine is added in common molecules list. Brand name needs to be changed.
566.	Csh-Zcal Tablet	Deferred since Application is devoid of following deficiencies: <ul style="list-style-type: none"> Form 3 is un-signed and un-stamped. Contents and brand name change undertakings are required. Fee evidence is required.
567.	Calzinc Tablet	Deferred for change of brand name.
568.	Zycolate Tablet	Deferred till finalization of common molecules list.
Sois Life Sciences, Karachi		
569.	Irowin Drop	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
570.	Zinglu Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
571.	Stall-D Drop	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
572.	Osteogel Cream	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
573.	Elett Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
574.	Bonform Sachet	Deferred for following reasons:

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
575.	Mefol-Dha Soft Gelatin Capsule	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
576.	Maximize Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
577.	Liverwin Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
578.	Iv-Mint Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
579.	Calwin-X Tablet	Deferred for change of brand name.
580.	Crany Sachet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
581.	Fat Burn Capsule	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
582.	Folica-400 Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
583.	Ivy-Dm Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
584.	Active-8 Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required.



S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> Brand name undertaking and content undertaking are required.
585.	Deep Relief Gel	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
586.	Cubex Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
587.	Q-Role Plus Soft Gelatin Capsule	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
588.	Growin Syrup	Deferred for change of brand name.
589.	Sunfit D Soft Gelatin Capsule	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
590.	Hydrobiotic Sachet	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
591.	Wintacid Suspension	Deferred till finalization of common molecules list.
592.	Bemalt Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
593.	Cal Win-X Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
594.	Befolic Tablet	Deferred for change of brand name.
595.	Pure Folic Soft Pearls Capsule	Deferred for change of brand name.
596.	Pure Multi Vitamins Tablet	Deferred for change of brand name.
597.	Pure Calcium Tablet	Deferred for change of brand name.
598.	Co Active Tablet	Deferred for change of brand name.
599.	Pure Epo Soft Gelatin Capsule	Deferred for change of brand name.
600.	Aminovit Sachet	Deferred for Availability of food supplement section and change of brand name.
Synicar Nutraceuticals, Rawalpindi		
601.	Neohope Syrup	Deferred for change of brand name.
602.	Cough B Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence.

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> Form 3 is required. Brand name undertaking and content undertaking are required.
Tehseen Industries, Lahore		
603.	Meco D'S Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Signed and stamped Form 3 is required. Brand name needs to be changed. N-acetyl cysteine is added in common molecules list.
Tarrot Health Care, Lahore		
604.	Max Natural Plus Sachet Sachet	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
605.	Dee-Drops Drops	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
606.	Ad More Drops Drops	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
Theramed Healthcare, Lahore		
607.	Huskit-C	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
Trends Pharmaceuticals Lahore		
608.	Hepa-Q Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
609.	Spasgon Tablet	Deferred for submission of monograph of basil.
610.	Hi-Zar Milk Sachet	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
611.	Mabso Iron Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Signed and stamped form 3 is required. Brand name change and contents undertakings are required. Fee evidence is required.
612.	Mabsocaltrat D Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Signed and stamped form 3 is required. Brand name change and contents undertakings are required. Fee evidence is required.

S.No	Brand name	Decision
(1)	(2)	(3)
613.	Mabsopreg Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Signed and stamped form 3 is required. Brand name change and contents undertakings are required. Fee evidence is required.
614.	Mom Milk Sachet	Deferred for following reasons: <ul style="list-style-type: none"> Strength of all ingredients per serving dose is required. Brand name needs to be changed.
615.	Nutracal-D Sachet	Deferred for change of brand name.
616.	Ener-G Tablet	Deferred till finalization of common molecules list.
617.	Qukuf +Syrup	Deferred for change of brand name.
618.	Allfixit Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
619.	Gusto Syrup	Deferred for following reasons: <ul style="list-style-type: none"> Signed and stamped form 3 is required. Brand name change and contents undertakings are required. Fee evidence is required.
620.	Vitashine Syrup	Deferred for change of brand name.
621.	Glomom Sachet	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
622.	Mabcentrum Specialist Tablet	Deferred due to following reasons: <ul style="list-style-type: none"> Beta sitosterol is added in common molecules list. Monograph of stinging nettle root extract and pygeum amricanum extract are required.
623.	Vitashine Tablet	Deferred for change of brand name.
Vernon Nutraceutical Pvt Ltd, Lahore		
624.	Malt-C Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Signed and stamped form 3 is required. Brand name change and contents undertakings are required. Fee evidence is required.
625.	Myositol-F Tablet	Deferred for change of brand name.
626.	Unical Tablet	Deferred for change of brand name.
627.	Bull Kraft Tablet	Deferred for change of brand name.
628.	Osteo-D Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
629.	Mega-Fol Tablet	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.

S.No (1)	Brand name (2)	Decision (3)
630.	Citra Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
631.	Bon-Z Tablet	Deferred for change of brand name.
632.	Ostco-D Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required. • Signed and stamped Form 3 is required. • Brand name needs to be changed.
633.	Bon-Z Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required. • Signed and stamped Form 3 is required. • Brand name needs to be changed.
634.	Mysoitol-F Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required. • Signed and stamped Form 3 is required. • Brand name needs to be changed.
Vida Laboratories, Karachi		
635.	Preymalt Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
636.	Perymalt-F Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required. • Brand name undertaking and content undertaking are required.
637.	Perymalt Syrup	Deferred for following reasons: <ul style="list-style-type: none"> • Strength of elemental iron in iron (III) hydroxide polymaltose complex is required. • Monograph of iron (III) hydroxide polymaltose complex is required.
638.	Vidacoline Syrup	Deferred till finalization of common molecules list.
639.	Vidacoline 500Mg Tablet	Deferred till finalization of common molecules list.
640.	Vidacoline 750Mg Tablet	Deferred till finalization of common molecules list.
641.	Vidacoline 1000Mg Tablet	Deferred till finalization of common molecules list.
642.	Relivac Plus Sachet	Deferred for submission of Safety profile of sambucus nigra extract is required since it is toxic (contains cyanogenic acid) and submission of monograph of purple coneflower extract.
643.	Relivac Sachet	Deferred for submission of Safety profile of sambucus nigra extract is required since it is toxic (contains cyanogenic acid).
644.	Ocutin 40Mg Soft gel Capsule	Deferred for submission of Individual Strength of lutein and zeaxanthin.
645.	Ocutin 20Mg Capsule	Deferred for submission of Individual Strength of lutein and zeaxanthin.
646.	Fevifol-D Sachet	Deferred for following reasons: <ul style="list-style-type: none"> • Signed and stamped form 3 is required. • Brand name change and contents undertakings are required. • Fee evidence is required.
647.	Glutamax Tablet	Deferred for following reasons: <ul style="list-style-type: none"> • Fee evidence is required alongwith R & I receiving evidence. • Form 3 is required.

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> Brand name undertaking and content undertaking are required.
648.	Covitak Softgel	Deferred for following reasons: <ul style="list-style-type: none"> Signed and stamped form 3 is required. Brand name change and contents undertakings are required. Fee evidence is required.
649.	Cokrill Plus Capsule	Deferred for submission of monograph of krill oil.
650.	Cokrill Softgel	Deferred for submission of monograph of krill oil.
Vital Mark Laboratories Pvt Ltd, Faisalabad		
651.	Vital Milk Grow powder	Deferred for following reasons: <ul style="list-style-type: none"> Justification of term by-pass fat and its use is required. Brand name needs to be changed.
652.	Tox Noll Plus Powder	Deferred with following deficiencies: <ul style="list-style-type: none"> Clarification of term organic acid required. Monograph of yeast cell wall is required. Justification of use of activated charcoal is required. Brand name needs to be changed.
653.	Vital Tox Noll Powder	Deferred for following reasons: <ul style="list-style-type: none"> Clarification of herbal extract and organic acids are required. Monograph of humic acid is required.
Wilson's Healthcare, Islamabad		
654.	Wilson'S Hi-C-Vita (Pomegranate)	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
655.	Wilson'S 3-Bion	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
656.	Wilson'S Hi-C-Vita (Orange)	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
657.	Wilson'S Hi-C-Vita (Cola)	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
658.	Wilson'S Aqua-Saline Nasal	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
659.	Wilson'S Hi-C-Vita (Pomegranate)	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required.

S.No (1)	Brand name (2)	Decision (3)
		<ul style="list-style-type: none"> Brand name undertaking and content undertaking are required.
660.	Wilson'S Hi-C-Vita (Red Grapes)	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
661.	Wilson'S Hi-C-Vita (Strawberry)	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
662.	Wilson'S Hi-Ckd (Orange)	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
663.	Wilson'S Hi-Ckd (Cola)	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
664.	Wilson'S Hi-Ckd (Red Grapes)	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
665.	Wilson'S Acrowil (Orange)	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
666.	Wilson'S Hi-Ckd (Strawberry)	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
667.	Wilson'S Hi-C-Vita (Orange)	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
668.	Wilson'S Hi-C-Vita (Strawberry)	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
669.	Wilson'S Hi-C-Vita (Cola)	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence.

S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> Form 3 is required. Brand name undertaking and content undertaking are required.
670.	Wilson'S Hi-C-Vita (Red Grapes)	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
671.	Wilson'S Acrowil (Orange)	Deferred for following reasons: <ul style="list-style-type: none"> Fee evidence is required alongwith R & I receiving evidence. Form 3 is required. Brand name undertaking and content undertaking are required.
M/s Adcok Pharmaceutical (Pvt) Ltd, Plot No 3-3-km, Defence off Raiwind Road ,Near Lahore Univerisity Lahore		
672.	Sentia mouthwash	Deferred for further deliberation.
673.	Lister Antisptic mouthwash	Deferred for further deliberation.
674.	Protack mouthwash	Deferred for further deliberation.
Falcon Laboratories (Pvt.) Limited, (E. No.00710) Special Industrial Estate, Behind Industrial Estate Office Risalpur, Nowshera		
675.	Neuroline Syrup	EEC decided to defer the application for enlistment for the change of brand name.


 (Ayyaz Ahmad)

Secretary, Enlistment Evaluation Committee

ANNEXURE

The firm is directed to submit soft data in both MS Excel & MS Word on following formats in **USB ONLY.**

MS Excel Format

Sr. No.	Company name	Product Name	Dosage Form	Composition	Common name	Recommended use	Pack Size	Date of R&I submission
1.	(Company name, City) Without address	XYZ	Tablet	Each tablet contains: Abc (USP)...50mg	XXX	XXX	10's 20's	DD.MM.YYYY
2.								

MS Word Format

Sr. No.	Company name	Product Name and composition	Common name	Recommended use	Pack Size
1.	(Company name, City) Without address	XYZ Tablet Each tablet contains: Abc (USP)...50mg	XXX	XXX	10's 20's
2.					